The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries

[1]  A. Serretti,et al.  Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. , 2021, Journal of psychiatric research.

[2]  C. Pae,et al.  Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis , 2021, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[3]  M. Osler,et al.  Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder. , 2021, Journal of affective disorders.

[4]  A. Young,et al.  Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. , 2021, The American journal of psychiatry.

[5]  Benjamin Sanders,et al.  Intranasal esketamine: From origins to future implications in treatment-resistant depression. , 2021, Journal of psychiatric research.

[6]  A. Serretti,et al.  Melancholic features in major depression – a European multicenter study , 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  G. Fava,et al.  Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. , 2020, JAMA psychiatry.

[8]  A. Young,et al.  Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance , 2020, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[9]  R. Baldessarini,et al.  Antidepressant responses in direct comparisons of melancholic and non-melancholic depression , 2020, Journal of psychopharmacology.

[10]  T. Furukawa,et al.  Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients , 2020, European Archives of Psychiatry and Clinical Neuroscience.

[11]  R. Fráguas,et al.  Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations , 2020, PloS one.

[12]  A. Rush,et al.  The identification, assessment and management of difficult-to-treat depression: An international consensus statement. , 2020, Journal of affective disorders.

[13]  T. Bschor,et al.  Antidepressants and suicidality: A re-analysis of the re-analysis. , 2020, Journal of affective disorders.

[14]  F. Defalco,et al.  Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019 , 2019, BMC Psychiatry.

[15]  C. Arangoc,et al.  The identification, assessment and management of difficult-to-treat depression_ An international consensus statement , 2020 .

[16]  Ashutosh Kumar Singh,et al.  Esketamine: a glimmer of hope in treatment-resistant depression , 2019, European Archives of Psychiatry and Clinical Neuroscience.

[17]  C. Zarate,et al.  The influence of ketamine on drug discovery in depression. , 2019, Drug discovery today.

[18]  G. Lewis,et al.  Newer-Generation Antidepressants and Suicide Risk , 2019, Psychotherapy and Psychosomatics.

[19]  E. Eriksson,et al.  Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. , 2019, The lancet. Psychiatry.

[20]  C. Nemeroff,et al.  Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. , 2019, Journal of psychiatric research.

[21]  B. Rive,et al.  The burden of suicidal ideation across Europe: a cross-sectional survey in five countries , 2019, Neuropsychiatric disease and treatment.

[22]  A. Serretti,et al.  Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice , 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[23]  M. Hengartner,et al.  Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-Analysis of the FDA Database , 2019, Psychotherapy and Psychosomatics.

[24]  S. Kasper,et al.  Prognosis and improved outcomes in major depression: a review , 2019, Translational Psychiatry.

[25]  David Taylor,et al.  Which first-line antidepressant? , 2019, The British journal of general practice : the journal of the Royal College of General Practitioners.

[26]  S. Lawrie,et al.  Pharmaco-epidemiology of antidepressant exposure in a UK cohort record-linkage study , 2019, Journal of psychopharmacology.

[27]  D. Martino,et al.  A quantitative review on outcome-to-antidepressants in melancholic unipolar depression , 2018, Psychiatry Research.

[28]  J. Ioannidis,et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.

[29]  H. Möller,et al.  Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder , 2018, International journal of methods in psychiatric research.

[30]  W. Brown,et al.  Decreased suicide rates in recent antidepressant clinical trials , 2018, Psychopharmacology.

[31]  A. Serretti,et al.  Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD) , 2018, The international journal of neuropsychopharmacology.

[32]  S. Crowe,et al.  A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples , 2018, Neuropsychology Review.

[33]  Nicole E. Carmona,et al.  Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. , 2018, Journal of affective disorders.

[34]  M. Manchia,et al.  Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review , 2016, Neuroscience Letters.

[35]  W. Ishak,et al.  The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder , 2018, Therapeutic advances in psychopharmacology.

[36]  J. López-Castromán,et al.  Antidepressants and suicide risk in depression , 2017, World psychiatry : official journal of the World Psychiatric Association.

[37]  S. Hofmann,et al.  Effect of treatments for depression on quality of life: a meta-analysis* , 2017, Cognitive behaviour therapy.

[38]  H. Möller,et al.  Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines , 2017, International journal of psychiatry in clinical practice.

[39]  P. Cuijpers,et al.  The effect of treatment as usual on major depressive disorder: A meta-analysis. , 2017, Journal of affective disorders.

[40]  S. Kasper,et al.  Evidence-based pharmacotherapy of treatment-resistant unipolar depression , 2017, International journal of psychiatry in clinical practice.

[41]  L. Bartova,et al.  Administration of ketamine for unipolar and bipolar depression , 2017, International journal of psychiatry in clinical practice.

[42]  A. Serretti,et al.  Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study , 2016, European Neuropsychopharmacology.

[43]  P. Blier,et al.  A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents , 2016, The international journal of neuropsychopharmacology.

[44]  A. Carvalho,et al.  The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature , 2016, Psychotherapy and Psychosomatics.

[45]  S. Stahl,et al.  A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature , 2015, European Neuropsychopharmacology.

[46]  T. Furukawa,et al.  Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. , 2015, Journal of affective disorders.

[47]  S. Ball,et al.  What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment , 2014, Annals of General Psychiatry.

[48]  Ying-Yue Wang,et al.  Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials , 2014, The Australian and New Zealand journal of psychiatry.

[49]  H. Möller,et al.  No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis , 2013, Annals of General Psychiatry.

[50]  A. Bradley,et al.  Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials , 2013, Journal of psychopharmacology.

[51]  A. Beekman,et al.  Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression , 2013, Molecular Psychiatry.

[52]  A. Serretti,et al.  European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings , 2012, European Neuropsychopharmacology.

[53]  R. Hanwella,et al.  Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies , 2012, International clinical psychopharmacology.

[54]  Roy H Perlis,et al.  A critical review of pharmacotherapy for major depressive disorder. , 2011, The international journal of neuropsychopharmacology.

[55]  Robert Michels,et al.  Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. , 2010, The American journal of psychiatry.

[56]  D. Gunnell,et al.  Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose , 2010, British Journal of Psychiatry.

[57]  R. DeRubeis,et al.  Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.

[58]  H. Möller,et al.  Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[59]  Rupert Lanzenberger,et al.  Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram , 2009, International clinical psychopharmacology.

[60]  H. Möller,et al.  The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. , 2009, The international journal of neuropsychopharmacology.

[61]  J. Geddes,et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.

[62]  K. Lohr,et al.  Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians , 2008, Annals of Internal Medicine.

[63]  Dan J Stein,et al.  Do SSRIs or antidepressants in general increase suicidality? , 2008, European Archives of Psychiatry and Clinical Neuroscience.

[64]  Patrick M Fisher,et al.  Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity , 2008, Neuropsychopharmacology.

[65]  Naomi A. Fineberg,et al.  Which antidepressants have demonstrated superior efficacy? A review of the evidence , 2007, International clinical psychopharmacology.

[66]  Julien Mendlewicz,et al.  Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. , 2007, The Journal of clinical psychiatry.

[67]  Maurizio Fava,et al.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.

[68]  H. Akiskal,et al.  Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. , 2005, Journal of affective disorders.

[69]  K. Behnke,et al.  Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study , 2003, Journal of clinical psychopharmacology.

[70]  A. Szegedi,et al.  Mirtazapine compared with paroxetine in major depression. , 2000, The Journal of clinical psychiatry.

[71]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[72]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[73]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.